S
ignificant evidence has demonstrated that ␤-adrenoreceptor blockade in the setting of stable, chronic heart failure can result in a dramatic improvement in left ventricular function and prognosis in patients with both ischemic and nonischemic cardiomyopathy. [1] [2] [3] [4] The pathophysiological basis for these clinical benefits, perhaps surprisingly, is not clearly established. A potential rationale for the use of ␤-adrenoreceptor blockade in heart failure is its effect to counteract the adverse metabolic effects of long-term sympathetic adrenergic system activation 5 and the resulting increased myocardial oxygen consumption. 6 In heart failure, myocardial energy efficiency is reduced. 7 It can be hypothesized that myocardial energy efficiency is reduced as a result of inappropriate, catecholamine-induced, enhanced free fatty acid (FFA) use secondary to elevated levels of serum FFAs acting as a metabolic substrate for the myocardium and within the myocardium itself by wasteful cycling of FFAs through intramyocardial lipolysis, reesterification, and suppression of glucose metabolism. 6,8 -10 ␤-Adrenoreceptor blockade in patients with heart failure improves myocardial energy efficiency, [11] [12] [13] [14] [15] [16] and a shift in myocardial substrate use from FFA to glucose oxidation 12 could contribute to the energy-sparing effects of this treatment.
In the present study, we evaluated the effect of a 3-month period of carvedilol treatment on regional myocardial FFA and glucose uptake in patients with stable New York Heart Association (NYHA) functional class III ischemic cardiomyopathy using positron emission tomography (PET) imaging with both the long-chain fatty acid tracer 14 . We hypothesized that a switch in myocardial energy substrate use from FFAs to glucose may be one potential mechanism for the improved energy efficiency seen in the treatment of patients with heart failure.
Methods

Patient Population
This study was reviewed and approved by the Human Subjects Committee at the University of Wisconsin at Madison. Nine patients were recruited from the University of Wisconsin Hospital and Clinics and the Madison Veterans Hospital (Table 1 ). All patients gave informed consent. All patients had left ventricular ejection fractions Յ35% and were on active treatment with an ACE inhibitor (if tolerated) and digitalis (unless contraindicated), with stable NYHA functional class III congestive heart failure at least 3 months before study entry. Left ventricular ejection fraction was determined by resting echocardiograms. No patient was taking ␤-adrenoreceptor blocking agents at the time of study entry. Exclusion criteria included a history of diabetes mellitus, severe or unstable angina, recent myocardial infarction (Ͻ3 months), and active alcohol/drug abuse. 
Carvedilol Treatment Regimen
Biochemical Analysis
Serum epinephrine and norepinephrine concentrations were determined by high-pressure liquid chromatography with electrochemical detection. 20 Nonesterified (free) fatty acid concentrations were measured by spectrophotometric enzymatic assay (Wako Chemicals). Plasma glucose concentrations were measured by a glucose oxidation assay (CX3-Delta Analyzer, Beckman Instruments, Inc).
Region of Interest Definition
To determine radiotracer time course, regions of interest were drawn within the myocardial borders in 3 contiguous midventricular transaxial slices of each subject. Myocardial slices were aligned between PET scans taken before and after carvedilol treatment, and identical regions of interest were pasted onto myocardial segments on [
18 F]-FTHA and [
18 F]-FDG scans. All 9 patients had thinned, akinetic left ventricular wall segments on echocardiography, which corresponded to metabolically inactive segments on PET images, suggesting infarcted myocardium. Regions of interest did not include these wall segments. Regions of interest were restricted to myocardial segments demonstrating relatively preserved contractility by echocardiography. PET myocardial transaxial slices were matched with the apical long-axis echocardiographic wall segments used to assess resting wall motion.
Data Analysis
Estimation of uptake rates from the PET time course data were performed with graphical analysis. 21 The myocardial uptake rates (K i ) for [ 18 F]-FTHA and [ 18 F]-FDG were first estimated from the following relation:
where C i indicates myocardial radioactivity; dt, derivative time; and C p , plasma [ Patients taking an ACE inhibitor, n 8/9
Patients taking digoxin, n 8/9
Patients taking cholesterol-lowering agents, n 6/9
Values are meanϮSEM or No. of patients.
Figure 1. Schematic of imaging protocol.
Myocardial oxygen consumption related to FFA use was estimated before and after carvedilol treatment using the following formula: 
Echocardiographic Evaluation
Echocardiograms were obtained using a Hewlett Packard Sonos 5500 ultrasound system before and after the completion of carvedilol treatment. Left ventricular regional wall motion was assessed by an experienced echocardiographer who was blinded to the carvedilol status of the patient. Two-dimensional echocardiographic estimation of left ventricular ejection fraction was calculated using Simpson's biplane method 23 with the Nova Microsonics ImageVue Workstation.
Statistical Analysis
The clinical and laboratory data of the patients are presented as meanϮSEM. Uptake rate data are presented as meanϮSEM. Comparing data before and after carvedilol treatment was done with a paired Student's t test. PϽ0.05 was considered statistically significant.
Results
Patient Characteristics
The study population was composed of 9 male patients with ischemic cardiomyopathy (Table 1 ). All patients received unchanged medical therapy for 3 months before enrollment. Patients were maintained on ACE inhibitors (89%), digoxin (89%), and diuretics (89%). Four patients (44%) were receiving hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), one (11%) was receiving gemfibrozil, and one was receiving an angiotensin II receptor blocker (11%). No patients were receiving ␤-adrenoreceptor blocking agents before the study. All patients were maintained on carvedilol treatment at 25 mg twice a day for at least 3 months (mean, 110Ϯ9 days).
Biochemical Data
The mean serum norepinephrine and epinephrine concentrations before carvedilol treatment were not significantly elevated and did not significantly change with carvedilol treatment ( Table 2 ). The mean serum FFA concentration before carvedilol treatment was elevated above the published normal range (0.40 to 0.66 mmol/mL), 24 and it did not significantly change after carvedilol treatment (0.92Ϯ0.27 mmol/L versus 0.88Ϯ0.24 mmol/L; PϭNS). The mean serum glucose concentration at baseline was within the normal range, and it did not significantly change after carvedilol treatment 
Hemodynamic and Echocardiographic Data
The mean resting heart rate decreased with carvedilol treat- 18 F]-FTHA uptake in patients with preserved left ventricular function who were treated with insulin infusion. In contrast to our findings, however, no effect of insulin on myocardial [ 18 F]-FTHA uptake rate constants (K i ) was observed, and effects were associated with a significant lowering of serum FFA concentration. Thus, the change in myocardial [ 18 F]-FTHA uptake in the study by Maki et al 25 was related to changes in substrate availability rather than the cellular handling of the substrate.
A potential explanation for our observed decrease in [
18 F]-FTHA uptake rate constants (K i ) after carvedilol therapy is a decrease in the activity of myocardial carnitine palmitoyl transferase I (CPT I), a key enzyme involved in mitochondrial FFA uptake. 26 Recent work by Panchal et al, 27 who used a canine model of heart failure, demonstrated a 28% decrease in the activity of CPT I after metoprolol treatment. Decreased CPT I activity by carvedilol could account for a significant lowering of myocardial FFA oxidation, and it provides a potential mechanism for the improved energy efficiency seen in patients with heart failure who are treated with ␤-adrenoreceptor blockade. 12 Although CPT I activity was not directly measured in our patients, DeGrado et al 18 previously demonstrated an 87% decrease in myocardial [
18 F]-FTHA uptake in mice treated with the CPT I inhibitor 2[5(4-chlorophenyl)pentyl] oxirane-2-carboxylate.
[
F]-FDG Imaging
No significant change in myocardial glucose use was seen in our patients. This finding is consistent with a relative switch in myocardial substrate use from FFA to glucose given the results of previous investigations demonstrating a reduction in myocardial oxygen consumption after ␤-blockade. 11, 12 Changes in lactate oxidation by the heart could contribute to the variability seen in myocardial glucose uptake in our study. The inhibition of CPT I activity is known to increase the activity of pyruvate dehydrogenase, 26, 28 which catalyzes the decarboxylation of pyruvate, 29 and the increased activity of this enzyme is expected to cause not only an increase in glucose oxidation, but an increase in lactate oxidation as well. 30 
Myocardial Energy Metabolism and Heart Failure
Alterations in myocardial energy metabolism that may occur in heart failure are somewhat controversial. We recently reported evidence of increased myocardial FFA and decreased myocardial glucose use in patients with heart failure using [
18 F]-FTHA and [ 18 F]-FDG. 31 These results are in agreement with the findings of previous human studies demonstrating an increase in myocardial FFA metabolism and a decrease in myocardial glucose metabolism in heart failure patients compared with controls using direct, invasive measurements of FFA and glucose metabolism. 7, 32 Conversely, animal studies have suggested a switch to a more fetal form of energy metabolism in heart failure, with increased glycolysis and suppression of FFA metabolism. 33, 34 Sack et al 35 showed a down-regulation of several genes involved in fatty acid metabolism in heart failure. Doenst et al 36 demonstrated an increase in glucose uptake with ␤-adrenergic stimulation, but other reports have not shown this increase. 37, 38 One explanation for the findings of Doenst et al 36 is that an increased lactate production and release of FFA on adrenergic stimulation results in increased availability of these substrates in the heart. The preference of the heart for the oxidation of lactate and FFA may then overwhelm the stimulatory effects of epinephrine on glucose metabolism, resulting in a net decrease of glucose uptake. 36 Although FFA oxidation is the major substrate for the heart and provides the highest yield of ATP (130 ATP per mole FFA versus 38 ATP per mole glucose), the metabolism of FFA requires more oxygen than glucose. The ATP yield for FFA per oxygen atom taken up is 2.83 compared with glucose at 3.17. 22 Therefore, myocardial FFA oxidation is less energy-efficient than glucose oxidation given the need for increased oxygen consumption for the same amount of ATP produced. Using the calculated myocardial FFA and glucose use rates in our patients, the amount of ATP produced decreased by 40% after carvedilol treatment. This decrease occurred despite the lack of a change in minute work, suggesting less energy is needed to perform the same amount of myocardial work after carvedilol treatment.
Estimated myocardial oxygen consumption related to FFA use fell by 57% after carvedilol treatment. This finding is consistent with previous studies demonstrating a significant decrease in myocardial oxygen consumption and improvement in myocardial energy efficiency with ␤-adrenoreceptor blockade. 11, 12 Although the mechanism for the improved energy efficiency is proposed to be the result of a switch from myocardial FFA oxidation to glucose oxidation, 12 this was not confirmed directly in our study.
The potential of ischemia and hibernation to alter myocardial metabolism was considered given the presence of underlying coronary artery disease in our patients. In the presence of ischemia, myocardial FFA oxidation is known to be suppressed and myocardial glucose oxidation is increased. 30 It is unlikely that significant myocardial ischemia affected our results given the high baseline myocardial FFA use and significant decrease in FFA use after carvedilol treatment seen in our patients. The effect of myocardial hibernation on myocardial FFA oxidation has also been previously evaluated with 18 F-FTHA by Maki et al. 39 They found no significant difference in 18 F-FTHA uptake in viable versus normal myocardial segments, suggesting that the presence of myocardial hibernation is unlikely to have affected our results.
Study Limitations
A control group was not included in this study because of overwhelming evidence supporting the use of ␤-blocker therapy in patients with heart failure, thus making it unethical to withhold this therapy from patients with heart failure.
Establishing a direct link between the changes in substrate use and a change in myocardial energy efficiency is difficult. Although factors other than a switch in myocardial substrate use may affect energy efficiency in patients with heart failure, the 57% reduction in myocardial FFA use seen in our study almost certainly led to a significant reduction in energy consumption by the heart.
Conclusions
Our results demonstrate carvedilol can significantly lower myocardial FFA use by 57% in patients with stable NYHA functional class III heart failure. This change in myocardial energetics could provide a potential mechanism for the decreased myocardial oxygen consumption and improved energy efficiency seen with ␤-adrenoreceptor blockade in the treatment of heart failure.
